("InnovaDerma" or the "Company")
InnovaDerma (LSE: IDP), a UK developer of life sciences, beauty and personal care products, announces that it was notified today that, Kieran Callan, Chief Executive Officer has purchased 3,500 Ordinary shares of €0.10 each in the Company at a price of 65 pence per Ordinary Share.
Following the Purchase, Kieran Callen now holds a total of 19,300 Ordinary Shares representing approximately 0.13% of the issued share capital of the Company.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Kieran Callan c/o TB Cardew
+61 (0)3 9863 8030
+44 (0)20 7930 0777
Geoff Nash/Kate Bannatyne
Alice Lane/Manasa Patil - Corporate Broking
+44 (0)207 220 0500
Shan Shan Willenbrock/Tom Allison
+ 44 (0)20 7930 0777
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities / person closely associated
Reason for the Notification
Chief Executive Offier
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the Financial instrument, type of instrument
€0.10 each ("Ordinary Shares")
Nature of the transaction
Purchase of Ordinary Shares
Price(s) and volume(s)
Volume - 3,500 Ordinary Shares
Price - 65 pence per Ordinary Share
See 4c) above
Date of the transaction
8 November 2019
Place of the transaction
London Stock Exchange, Main Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.